ACET supply chain intelligence for Adicet Bio, Inc.: verified suppliers, customers, debt relationships, acquisitions, and ownership data.
Data compiled by Redley Lamar · ChainSifter Intelligence
Adicet Bio, Inc. (ACET) is shown with relationship data already present in ChainSifter's database. Counts below come from stored supply-chain records and filing/source URLs where available; missing source URLs are not filled in or estimated.
| Ticker | Name | Confidence | Evidence |
|---|---|---|---|
| CRSP | CRISPR Therapeutics AG | 90% | The Company entered into a license and collaboration agreement with CRISPR Therapeutics AG (CRISPR Agreement) to non-exclusively license CRISPR’s gene editing technology (CRISPR Technology) for use i… |
| CRSP | CRISPR Therapeutics AG | 90% | Reciprocal relationship from CRSP graph: Reciprocal relationship from ACET graph: Reciprocal relationship from CRSP graph: Reciprocal relationship from ACET graph: The Company entered into a license … |
| TWST | Twist Bioscience Corporation | 90% | Reciprocal relationship from TWST graph: Reciprocal relationship from ACET graph: Reciprocal relationship from TWST graph: Reciprocal relationship from ACET graph: Reciprocal relationship from TWST g… |
| TWST | Twist Bioscience Corporation | 90% | The Company will pay Twist an upfront, non-refundable project initiation fee, a technology access fee, as well as a project fee for each project entered into under the agreement. |
| COHORT-PHARMACEUTICALS-INC | COHORT-PHARMACEUTICALS-INC | 85% | The Company may pay fees for development and regulatory milestones that together total in the single digit millions of dollars and sales milestones in the low-to-mid double digit millions of dollars. |
| GDTC | CytoMed Therapeutics Limited | 72% | Reciprocal relationship from GDTC graph: l expansion. ATPL retained the right to use all products and/or services the Company creates which contain or incorporate the modified human K562 cells. Any n… |
| REGN | Regeneron Pharmaceuticals, Inc. | 72% | Reciprocal relationship from REGN graph: Reciprocal relationship from ACET graph: Reciprocal relationship from REGN graph: Reciprocal relationship from ACET graph: Reciprocal relationship from REGN g… |
| Ticker | Name | Confidence | Evidence |
|---|---|---|---|
| ARTV | Artiva Biotherapeutics, Inc. | 72% | Reciprocal relationship from ARTV graph: Reciprocal relationship from ACET graph: Reciprocal relationship from ARTV graph: Reciprocal relationship from ACET graph: Reciprocal relationship from ARTV g… |
| CRSP | CRISPR Therapeutics AG | 72% | ancial institution currently in receivership, if any of our lenders or counterparties to any such instruments were to be placed into receivership, we may be unable to access such funds. In addition, … |
| CRSP | CRISPR Therapeutics AG | 72% | Reciprocal relationship from CRSP graph: Reciprocal relationship from ACET graph: ancial institution currently in receivership, if any of our lenders or counterparties to any such instruments were to… |
| GDTC | CytoMed Therapeutics Limited | 72% | Reciprocal relationship from GDTC graph: Reciprocal relationship from ACET graph: Reciprocal relationship from GDTC graph: ign or implementation of our pre-clinical studies and clinical trials; ● cha… |
| REGN | Regeneron Pharmaceuticals, Inc. | 72% | Reciprocal relationship from REGN graph: Reciprocal relationship from ACET graph: Reciprocal relationship from REGN graph: Reciprocal relationship from ACET graph: Reciprocal relationship from REGN g… |
| REGN | Regeneron Pharmaceuticals, Inc. | 72% | f Shanghai Adicet from its then-stockholders (the Acquisition). In connection with the Acquisition, tax filings and registration were completed in August 2025. In August 2025, upon completion of the … |
| TWST | Twist Bioscience Corporation | 72% | Reciprocal relationship from TWST graph: Reciprocal relationship from ACET graph: Reciprocal relationship from TWST graph: Reciprocal relationship from ACET graph: Reciprocal relationship from TWST g… |
| TWST | Twist Bioscience Corporation | 72% | ancial institution currently in receivership, if any of our lenders or counterparties to any such instruments were to be placed into receivership, we may be unable to access such funds. In addition, … |
| GUGGENHEIM-SECURITIES-LLC | GUGGENHEIM-SECURITIES-LLC | 62% | f Shanghai Adicet from its then-stockholders (the Acquisition). In connection with the Acquisition, tax filings and registration were completed in August 2025. In August 2025, upon completion of the … |
| SI | Shoulder Innovations, Inc. | 62% | Reciprocal relationship from SI graph: Reciprocal relationship from ACET graph: velop or use AI systems that are governed by the AI Act, it may necessitate ensuring higher standards of data quality, … |
| SILVERGATE-CAPITAL-CORP | SILVERGATE-CAPITAL-CORP | 62% | velop or use AI systems that are governed by the AI Act, it may necessitate ensuring higher standards of data quality, transparency, and human oversight, as well as adhering to specific and potential… |
| Instrument | Description | Confidence | Evidence |
|---|---|---|---|
| ACET-DEBT | Debt stack $13.9M | 90% | Market cache reports total debt of $13.9M. |
| ACET-DEBT-7456 | Xbrl Convertible | 90% | xbrl convertible detail from xbrl 2020-12-31. |
| ACET-DEBT-7455 | Warrants outstanding: 38.3984 | 90% | xbrl warrant detail from xbrl 2025-12-31. |
| Acquired Entity | Name | Confidence | Evidence |
|---|---|---|---|
| ACET-ACQ-0001720580-26-000023 | Adicet Bio, Inc. issued a pre-funded warrant to acquire 250,000 shares of common stock. | 85% | Adicet Bio, Inc. issued a pre-funded warrant to acquire 250,000 shares of common stock. |
| Holder | Name | Confidence | Evidence |
|---|---|---|---|
| ACET-OWNER-BARCLAYS-PLC | BARCLAYS PLC | 90% | 13F overlay lists BARCLAYS PLC as top holder; 5 tracked holders. |
| Ticker | Name | Chain Index | Hops | Relationship Types |
|---|---|---|---|---|
| CRSP | CRISPR Therapeutics AG | 100.00 | 1 | ['customer', 'supplier'] |
| TWST | Twist Bioscience Corporation | 100.00 | 1 | ['customer', 'supplier'] |
| VERTEX | VERTEX | 100.00 | 2 | |
| ARTV | Artiva Biotherapeutics, Inc. | 100.00 | 1 | ['customer'] |
| REGN | Regeneron Pharmaceuticals, Inc. | 100.00 | 1 | ['customer', 'supplier'] |
| SI | Shoulder Innovations, Inc. | 100.00 | 1 | ['customer'] |
| GDTC | CytoMed Therapeutics Limited | 100.00 | 1 | ['customer', 'supplier'] |
| CAN | Canaan Inc. | 50.00 | 2 | |
| CRBU | Caribou Biosciences, Inc. | 50.00 | 2 | |
| BLSH | Bullish | 50.00 | 2 | |
| GEMI | Gemini Space Station, Inc. | 50.00 | 2 | |
| IRON | Disc Medicine, Inc. | 50.00 | 2 | |
| ALLO | Allogene Therapeutics, Inc. | 50.00 | 2 | |
| CTMX | CytomX Therapeutics, Inc. | 50.00 | 2 | |
| CHRS | Coherus Oncology, Inc. | 50.00 | 2 | |
| EDSA | Edesa Biotech, Inc. | 50.00 | 2 | |
| ANTA | Antalpha Platform Holding Compa | 50.00 | 2 | |
| FATE | Fate Therapeutics, Inc. | 50.00 | 2 | |
| TAOP | Taoping Inc. | 50.00 | 2 | |
| CHKP | Check Point Software Technologies Ltd. | 50.00 | 2 |